文献速递血管炎

阿伐可泮在接受利妥昔单抗治疗的ANCA相关性血管炎患者中的疗效与安全性:一项随机试验

Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
PubMed 文献 · Ann Rheum Dis · 2024-01-11

ADVOCATE试验中接受利妥昔单抗背景诱导治疗的214例ANCA相关性血管炎患者中,阿伐可泮组第26周缓解率和第52周持续缓解率与泼尼松减量组相似(第52周更高),且肾脏结局更好、糖皮质激素毒性更低。

要点

  • 第26周缓解率:阿伐可泮组77.6% vs 泼尼松减量组75.7%。
  • 第52周持续缓解率:阿伐可泮组71.0% vs 泼尼松减量组56.1%。
  • 严重不良事件发生率:阿伐可泮组34.6% vs 泼尼松减量组39.3%。

核心结论

  • 在接受利妥昔单抗的ANCA相关性血管炎患者中,阿伐可泮的疗效在第26周与泼尼松减量相似,在第52周更优,且安全性良好。
  • 阿伐可泮与肾脏结局改善和糖皮质激素毒性降低相关。

研究设计与样本

  • ADVOCATE试验(NCT02994927)中接受利妥昔单抗背景诱导治疗的患者亚组分析。
  • 330例接受研究药物的患者中214例(64.8%)接受利妥昔单抗(每周一次,共4周),平均年龄59.8岁。
  • 163例(76.2%)有肾血管炎,125例(58.4%)为新诊断。

主要发现

  • 第26周缓解率:阿伐可泮组83/107(77.6%)vs 泼尼松减量组81/107(75.7%)。
  • 第52周持续缓解率:阿伐可泮组76/107(71.0%)vs 泼尼松减量组60/107(56.1%)。
  • 严重不良事件发生率:阿伐可泮组34.6% vs 泼尼松减量组39.3%。
  • 复发率、肾功能恢复、白蛋白尿下降速度和糖皮质激素毒性均有利于阿伐可泮组。

关键数值与推荐

  • 主要疗效结局为第26周缓解和第52周持续缓解。
  • 其他结局包括糖皮质激素毒性指数、估算肾小球滤过率、尿白蛋白与肌酐比值、健康相关生活质量和安全性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of avacopan in the subgroup of patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis receiving background induction therapy with rituximab in the phase 3 ADVOCATE trial. METHODS: Key efficacy outcomes were remission at week 26 and sustained remission at week 52. Additional outcomes included the Glucocorticoid Toxicity Index, estimated glomerular filtration rate, urinary albumin to creatinine ratio, health-related quality of life and safety. RESULTS: Of the 330 patients who received study medication, 214 (64.8%) received rituximab (once weekly for 4 weeks), with a mean age of 59.8 years; 163 (76.2%) had renal vasculitis and 125 (58.4%) were newly diagnosed. Remission at week 26 and sustained remission at week 52 were achieved by 83/107 (77.6%) and 76/107 (71.0%) patients in the avacopan group and 81/107 (75.7%) and 60/107 (56.1%) in the prednisone taper group, respectively. The relapse rate, recovery of renal function, speed of reduction in albuminuria and glucocorticoid toxicity favoured the avacopan group. Serious adverse events occurred in 34.6% and 39.3% of patients in the avacopan and prednisone taper groups, respectively. CONCLUSIONS: These data suggest that in patients with ANCA-associated vasculitis receiving rituximab, efficacy of treatment with avacopan compared with a prednisone taper was similar at week 26 and greater at week 52, with a favourable safety profile. In addition, avacopan was associated with improved renal outcomes and lower glucocorticoid toxicity. These results demonstrate the efficacy and safety of avacopan in patients receiving background induction therapy with rituximab. TRIAL REGISTRATION NUMBER: NCT02994927.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Geetha D, Dua A, Yue H, et al. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis. 2024. PMID: 37979959. doi:10.1136/ard-2023-224816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。